related documents
- APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa Conferences
- Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease from OFF to fully ON Conferences
- Minimum MDS-UPDRS part III change needed to convert a Parkinson's disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277) Conferences
- Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study Conferences
- Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson's disease Conferences
- Treatment of OFF episodes in Parkinson's disease: An evaluation of patient and caregiver insights Conferences
- Treatment of OFF episodes in Parkinson's disease: An evaluation of physician practices Conferences